


Amendments to the claims

1. (currently amended) A compound of Formula (I):



(I)

or a stereoisomer, or pharmaceutically acceptable salt form thereof, wherein:

A¹ is C₁-C₃ alkylene substituted by 0-2 C₁-C₄ alkyl;

$$A^2 \text{ is } -A^3 - R^9 a;$$
$$W \text{ is } -B(OR^{26})(OR^{27});$$

R^1 is selected from the group: H, F;

C₁-C₆ alkyl substituted with 0-3 R^{1a};

C₂-C₆ alkenyl substituted with 0-3 R^{1a};

C₂-C₆ alkynyl substituted with 0-3 R^{1a}; and

C₃-C₆ cycloalkyl substituted with 0-3 R^{1a};

R^{1a} is selected at each occurrence from the group:

Cl, F, Br, I, CF₃, CHF₂, OH, =O, SH;

R² is selected from the group: H, C₁-C₄ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, C₃-C₄ cycloalkyl, and C₃-C₄ cycloalkyl(C₁-C₄ alkyl)-;

R^3 is selected from the group: R^4 ,

$-(CH_2)_p-NH-R^4$,
 $-(CH_2)_p-NHC(=O)-R^4$,
 $-(CH_2)_p-C(=O)NH-R^4$,
 $-(CH_2)_p-C(=O)O-R^4$,
 $-(CH_2)_p-C(=O)C(=O)-R^4$,
 $-(CH_2)_p-C(=O)C(=O)NH-R^4$,
 $-(CH_2)_p-NHC(=O)NH-R^4$,
 $-(CH_2)_p-NHC(=O)NHC(=O)-R^4$,
 $-(CH_2)_p-NHS(=O)_2-R^4$,
 $-(CH_2)_p-S(=O)_2NH-R^4$,
 $-(CH_2)_p-C(=O)-R^4$,
 $-(CH_2)_p-O-R^4$, and
 $-(CH_2)_p-S-R^4$;

p is 0, 1, or 2;

R^4 is selected from the group:

C_1 - C_6 alkyl substituted with 0-3 R^{4a} ;
 C_2 - C_6 alkenyl substituted with 0-3 R^{4a} ;
 C_2 - C_6 alkynyl substituted with 0-3 R^{4a} ; and
 ~~C_3 - C_{10} cycloalkyl substituted with 0-4 R^{4b} ;~~
 C_3 - C_{10} carbocycle substituted with 0-4 R^{4b} ;
~~aryl substituted with 0-5 R^{4b} ; and~~
~~aryl- C_1 - C_4 alkyl substituted with 0-5 R^{4b} ;~~

R^{4a} is, at each occurrence, independently selected from:

H,

C₁-C₄ alkyl substituted with 0-3 R^{4b};

C₂-C₄ alkenyl substituted with 0-3 R^{4b};

C₂-C₄ alkynyl substituted with 0-3 R^{4b}; and

~~C₃-C₇ cycloalkyl substituted with 0-4 R^{4e};~~

C₃-C₁₀ carbocycle substituted with 0-4 R^{4c}; and

~~aryl substituted with 0-5 R^{4e};~~

R^{4b} is, at each occurrence, independently selected from:

H,

C₁-C₄ alkyl substituted with 0-3 R^{4c};

C₂-C₄ alkenyl substituted with 0-3 R^{4c};

C₂-C₄ alkynyl substituted with 0-3 R^{4c};

C₃-C₆ cycloalkyl substituted with 0-4 R^{4d}; and

aryl substituted with 0-5 R^{4d};

R^{4c} is, at each occurrence, independently selected from:

H,

C₁-C₄ alkyl substituted with 0-3 R^{4d};

C₂-C₄ alkenyl substituted with 0-3 R^{4d};

C₂-C₄ alkynyl substituted with 0-3 R^{4d};

C₃-C₆ cycloalkyl substituted with 0-4 R^{4d}; and

aryl substituted with 0-5 R^{4d};

R^{4d} is, at each occurrence, independently selected from:

H, F, Cl, Br, I, -NO₂, -CN, -NCS, -CF₃, -OCF₃, =O, OH,

R^{9a} is selected from the group: H, ~~-S(=O)₂R^{9b}~~,
-C(=O)R^{9b}, -C(=O)OR^{9b}, -C(=O)NHR^{9b}, -C(=O)NHC(=O)R^{9b};
C₁-C₆ alkyl substituted with 0-3 R^{9c};
C₂-C₆ alkenyl substituted with 0-3 R^{9c}; and
C₂-C₆ alkynyl substituted with 0-3 R^{9c};

R^{9b} is selected from the group: H;
C₁-C₆ alkyl substituted with 0-3 R^{9c};
C₂-C₆ alkenyl substituted with 0-3 R^{9c};
C₂-C₆ alkynyl substituted with 0-3 R^{9c}; and
~~C₃-C₆ cycloalkyl substituted with 0-3 R^{9d},~~
C₃-C₁₄ carbocycle substituted with 0-4 R^{9d}; and
~~aryl substituted with 0-5 R^{9d},~~

R^{9c} is selected from the group:
C₁-C₆ alkyl substituted with 0-3 R^{9d};
C₂-C₆ alkenyl substituted with 0-3 R^{9d};
C₂-C₆ alkynyl substituted with 0-3 R^{9d}; and
~~C₃-C₆ cycloalkyl substituted with 0-3 R^{9e},~~
C₃-C₁₄ carbocycle substituted with 0-4 R^{9e}; and
~~aryl substituted with 0-5 R^{9e},~~

R^{9d} is selected at each occurrence from the group:
C₁-C₄ alkyl substituted with 0-3 R^{9e};
C₁-C₄ alkoxy substituted with 0-3 R^{9e};
C₃-C₆ cycloalkyl substituted with 0-3 R^{9e}; and

aryl substituted with 0-5 R^{9e};

R^{9e} is selected at each occurrence from the group:

C₁-C₄ alkyl, C₁-C₄ alkoxy, CF₃, OCF₃, Cl, F, Br, I, =O, OH,
phenyl, C(O)OR¹¹, NH₂, NH(CH₃), N(CH₃)₂, -CN, and NO₂;

~~R¹¹ and R^{11a} are, at each occurrence, independently~~ is selected
from the group: H;

C₁-C₆ alkyl substituted with 0-3 R^{11b};

C₂-C₆ alkenyl substituted with 0-3 R^{11b};

C₂-C₆ alkynyl substituted with 0-3 R^{11b};

C₃-C₇ cycloalkyl substituted with 0-3 R^{11b};

aryl substituted with 0-3 R^{11b}; and

aryl(C₁-C₄ alkyl)- substituted with 0-3 R^{11b};

R^{11b} is OH, C₁-C₄ alkoxy, F, Cl, Br, I, NH₂, or -NH(C₁-C₄ alkyl);

~~OR²⁶ and OR²⁷ are independently selected from:~~

~~a) OH,~~

~~b) C₁-C₈ alkoxy, and~~

, when taken together, OR²⁶ and OR²⁷ form a cyclic boronic
ester where said cyclic boronic ester contains from 2 to 20
carbon atoms; and

A³ is valine.

2. (currently amended) A compound of Claim 1, or a stereoisomer, or
a pharmaceutically acceptable salt form thereof, wherein:

A¹ is -CH₂-;

R¹ is selected from the group: H,

C₁-C₆ alkyl;

C₂-C₆ alkenyl; and

C₂-C₆ alkynyl;

R² is H;

R³ is selected from the group:

C₁-C₆ alkyl substituted with phenyl,

C₁-C₆ alkenyl substituted with phenyl, and

~~-CH₂CONHPh, and~~

~~(2-phenylquinolin-4-yl)methyl;~~

and OR²⁶ and OR²⁷ ~~when~~ taken together form pinanediol.

3. (previously canceled)

4. (previously canceled)

5. (previously canceled)

6. (previously canceled)

7. (currently amended) A compound of Claim 1, or a stereoisomer or a pharmaceutically acceptable salt form thereof, selected from the group consisting of

(4S)-N-{[[[(1R)-1-[(3 α S, 4S, 6S, 7 α R)-hexahydro-3 α , 5, 5-trimethyl-4, 6-methano-1, 3, 2-benzodioxaborol-2-yl]propyl]-3-[(2S)-3-methyl-2-[(phenylacetyl)-amino]-butanoyl]-2-oxo-1-(3-phenylpropyl)-4-imidazolidinecarboxamide;

tert-butyl (1S)-N-{[[[(1R)-1-[(3 α S, 4S, 6S, 7 α R)-hexahydro-3 α , 5, 5-trimethyl-4, 6-methano-1, 3, 2-benzodioxaborol-2-yl]propyl]amino)carbonyl]-2-oxo-3-(3-phenylpropyl)imidazolidinyl]carbonyl]-2-methylpropylcarbamate;

(4S)-N-{[[[(1R)-1-[(3 α S, 4S, 6S, 7 α R)-hexahydro-3 α , 5, 5-trimethyl-4, 6-methano-1, 3, 2-benzodioxaborol-2-yl]propyl]-3-[(2S)-2-[(anilino)carbonyl]amino]-3-methylbutanoyl]-2-oxo-1-(3-phenylpropyl)-4-imidazolidinecarboxamide;

(4S)-N-{[[[(1R)-1-[(3 α S, 4S, 6S, 7 α R)-hexahydro-3 α , 5, 5-trimethyl-4, 6-methano-1, 3, 2-benzodioxaborol-2-yl]propyl]-3-[(2S)-2-[(9H-fluoren-1-yl)carbonyl]amino]-3-methylbutanoyl]-2-oxo-1-(3-phenylpropyl)-4-imidazolidinecarboxamide;

(4S)-N-{[[[(1R)-1-[(3 α S, 4S, 6S, 7 α R)-hexahydro-3 α , 5, 5-trimethyl-4, 6-methano-1, 3, 2-benzodioxaborol-2-yl]propyl]-3-[(2S)-2-[(4-methoxyphenyl)acetyl]amino]-3-methylbutanoyl]-2-oxo-1-(3-phenylpropyl)-4-imidazolidinecarboxamide;

(4S)-N-{[[[(1R)-1-[(3 α S, 4S, 6S, 7 α R)-hexahydro-3 α , 5, 5-trimethyl-4, 6-methano-1, 3, 2-benzodioxaborol-2-yl]-3-butenyl]-3-[(2S)-2-[(9H-fluoren-1-yl)carbonyl]amino]-3-methylbutanoyl]-2-oxo-1-(3-phenylpropyl)-4-imidazolidinecarboxamide;

9H-fluoren-9-ylmethyl (1S)-N-{[[[(1R)-1-[(3αS,4S,6S,7αR)-hexahydro-3α,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]amino)carbonyl]-2-oxo-3-(3-phenylpropyl)imidazolidinyl]carbonyl}-2-methylpropylcarbamate;

(4S)-N-{[[[(1R)-1-[(3αS,4S,6S,7αR)-hexahydro-3α,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]-3-((2S)-3-methyl-2-{[3-(trifluoromethyl)benzyl]amino}butanoyl)-2-oxo-1-(3-phenylpropyl)-4-imidazolidinecarboxamide;

(4S)-N-{[[[(1R)-1-[(3αS,4S,6S,7αR)-hexahydro-3α,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]-3-((2S)-2-[[[1,1'-biphenyl]-4-ylmethyl]amino]-3-methylbutanoyl)-2-oxo-1-(3-phenylpropyl)-4-imidazolidinecarboxamide;

~~9H-fluoren-9-ylmethyl (1S)-1-((5S)-5-[[[(1R)-1-[(3αS,4S,6S,7αR)-hexahydro-3α,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]amino)carbonyl]-2-oxo-3-[(2-phenyl-4-quinolinyl)methyl]imidazolidinyl]carbonyl)-2-methylpropylcarbamate;~~

~~N-((1S)-1-((5S)-5-[[[(1R)-1-[(3αS,4S,6S,7αR)-hexahydro-3α,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]-amino)carbonyl]-2-oxo-3-(3-phenylpropyl)imidazolidinyl]carbonyl)-2-methylpropyl)-2-chloronicotinamide;~~

(4S)-N-{[[[(1R)-1-[(3αS,4S,6S,7αR)-hexahydro-3α,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]propyl]-3-((2S)-2-[(4-

butylbenzoyl) amino]-3-methylbutanoyl]-2-oxo-1-(3-phenylpropyl)-4-imidazolidinecarboxamide;

isobutyl (1*S*)-1-{[(5*S*)-5-{[(1*R*)-1-[(3*αS*, 4*S*, 6*S*, 7*αR*)-hexahydro-3*α*, 5, 5-trimethyl-4, 6-methano-1, 3, 2-benzodioxaborol-2-yl]propyl} amino) carbonyl]-2-oxo-3-(3-phenylpropyl) imidazolidinyl] carbonyl]-2-methylpropylcarbamate;

(4*S*)-*N*-{[(1*R*)-1-[(3*αS*, 4*S*, 6*S*, 7*αR*)-hexahydro-3*α*, 5, 5-trimethyl-4, 6-methano-1, 3, 2-benzodioxaborol-2-yl]propyl]-3-[(2*S*)-2-[(benzoylamino) carbonyl] amino]-3-methylbutanoyl]-2-oxo-1-(3-phenylpropyl)-4-imidazolidinecarboxamide;

(4*S*)-*N*-{[(1*R*)-1-[(3*αS*, 4*S*, 6*S*, 7*αR*)-hexahydro-3*α*, 5, 5-trimethyl-4, 6-methano-1, 3, 2-benzodioxaborol-2-yl]propyl]-3-[(2*S*)-3-methyl-2-(1-naphthoylamino) butanoyl]-2-oxo-1-(3-phenylpropyl)-4-imidazolidinecarboxamide;

(4*S*)-*N*-{[(1*R*)-1-[(3*αS*, 4*S*, 6*S*, 7*αR*)-hexahydro-3*α*, 5, 5-trimethyl-4, 6-methano-1, 3, 2-benzodioxaborol-2-yl]propyl]-3-[(2*S*)-2-(acetylamino)-3-methylbutanoyl]-2-oxo-1-(3-phenylpropyl)-4-imidazolidinecarboxamide;

(4*S*)-*N*-{[(1*R*)-1-[(3*αS*, 4*S*, 6*S*, 7*αR*)-hexahydro-3*α*, 5, 5-trimethyl-4, 6-methano-1, 3, 2-benzodioxaborol-2-yl]propyl]-3-[(2*S*)-2-(benzoylamino)-3-methylbutanoyl]-2-oxo-1-(3-phenylpropyl)-4-imidazolidinecarboxamide;

benzyl (5*S*)-5-[(1*R*)-1-[(3*αS*, 4*S*, 6*S*, 7*αR*)-hexahydro-3*α*, 5, 5-trimethyl-4, 6-methano-1, 3, 2-benzodioxaborol-2-yl]-3-

butenyl}amino) carbonyl]-2-oxo-3-[(2*E*)-3-phenyl-2-propenyl]-1-imidazolidinecarboxylate; and

benzyl (5*S*)-5-[(1*R*)-1-[(3*αS*, 4*S*, 6*S*, 7*αR*)-hexahydro-3*α*, 5, 5-trimethyl-4, 6-methano-1, 3, 2-benzodioxaborol-2-yl]-3-butenyl}amino) carbonyl]-3-(2-anilino-2-oxoethyl)-2-oxo-1-imidazolidinecarboxylate.

8. (previously amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Claim 1, or a pharmaceutically acceptable salt form thereof.

9. (previously canceled)

10. (previously canceled)

11. (previously canceled)

12. (previously canceled)

13. (previously canceled)

14. (previously canceled)

15. (previously canceled)

16. (previously canceled)

17. (previously canceled)

18. (previously canceled)

19. (previously canceled)

20. (previously canceled)

21. (previously canceled)

22. (previously canceled)